FOLH1 and cancer: For instance, several nanoformulations currently undergoing clinical testing seek to improve the effectiveness of cancer treatment through active targeting (e.g., BIND-014: PSMA-directed docetaxel nanoparticle) and stimuli-responsive drug release (e.g., ThermoDox: lyso-thermosensitive liposomal doxorubicin).